annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 13C Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in
SEER-Medicare. (Abstract #4658)
E. Onukwugha, M. Grabner, C. D. Mullins, B. S. Seal, A. Hussain
Brd. 13D Characteristics of men with abnormal prostate-specific antigen (PSA) who
had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO). (Abstract #4659)
W. G. Hocking, C. McCarty, T. Riley, T. Hickey, J. K. Burmester, D. Reding
Brd. 13E Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant
prostrate cancer (CPRC). (Abstract #4660)
G. C. Buckle, L. Werner, W. K. Oh, G. Bubley, J. H. Hayes, D. Weckstein, A. Elfiky,
D. M. Sims, P. Kantoff, M. Taplin
Brd. 13F A phase II study of oral phenoxodiol in castrate and noncastrate prostate
cancer patients with associated cytokine changes. (Abstract #4661)
G. Gibney, A. Elfiky, S. Bussom, C. J. Hoimes, A. Burns, J. A. McDonough,
E. Rowen, Y. C. Cheng, W. K. Kelly
Brd. 13G A phase II study of preoperative figitumumab (F) in patients (pts) with
localized prostate cancer (PCa). (Abstract #4662)
K. N. Chi, M. E. Gleave, L. Fazli, S. L. Goldenberg, A. So, C. K. Kollmannsberger,
N. Murray, A. Tinker, A. Gualberto, M. N. Pollak
Brd. 13H Modulation of candidate therapy targets in regionally advanced prostate
cancer by androgen ablation and docetaxel. (Abstract #4663)
V. Tzelepi, E. Efstathiou, P. Troncoso, C. A. Pettaway, A. Hoang, C. Logothetis,
L. C. Pagliaro
Brd. 14A Phase I study of the specific endothelin A receptor antagonist zibotentan
(ZD4054) combined with docetaxel in patients with metastatic castrationresistant
prostate cancer: Assessment of efficacy, pain, and safety.
(Abstract #4664)
D. L. Trump, H. Payne, K. Miller, J. S. De Bono, J. Stephenson, H. A. Burris III,
F. E. Nathan, M. Taboada, T. Morris, A. Hübner
Brd. 14B Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and
monocyte chemotactic protein-1 (MCP-1) levels in patients with castrationresistant
progressive prostate cancer (CRPC). (Abstract #4665)
F. Dayyani, G. E. Gallick, J. T. Thompson, G. C. Trudel, C. Logothetis, J. C. Araujo
Brd. 14C Cetuximab in combination with docetaxel in patients (pts) with metastatic
castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A
multicenter phase II trial (SAKK 08/07). (Abstract #4666)
R. Cathomas, C. Rothermundt, R. von Moos, D. C. Betticher, R. C. Winterhalder,
C. Droege, D. Siciliano, D. R. Berthold, M. Pless, S. Gillessen
Brd. 14D Phase I trial of fractionated-dose 177 lutetium radiolabeled anti-prostatespecific
membrane antigen (PSMA) monoclonal antibody J591 ( 177 Lu-J591) in
patients (pts) with metastatic castration-resistant prostate cancer
(metCRPC). (Abstract #4667)
S. T. Tagawa, S. Vallabhajosula, J. Osborne, S. J. Goldsmith, K. Petrillo, L. Tyrell,
G. S. Dhillon, H. Beltran, N. H. Bander, D. M. Nanus
Brd. 14E Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803):
Effect of Kras and EGFR status on clinical outcome. (Abstract #4668)
Y. Chen, J. Kolesar, W. Huang, R. S. DiPaola, M. Pins, M. A. Carducci, M. N. Stein,
G. Bubley, G. Wilding, G. Liu
Brd. 14F Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody
in castration-resistant prostate cancer (CRPC). (Abstract #4669)
M. A. Carducci, M. A. Eisenberger, S. R. Denmeade, S. F. Slovin, A. Jakobovits,
M. Vincent, H. I. Scher, M. J. Morris
Brd. 14G The effect of inhibition of the insulin-like growth factor receptor with
nordihydroguaiaretic acid on PSA progression: Results of a phase II study.
(Abstract #4670)
T. W. Friedlander, V. K. Weinberg, C. Formaker, J. Mi, A. M. Lin, A. L. Harzstark,
L. Fong, E. J. Small, C. J. Ryan
366